• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.开发哺乳动物悬浮培养体系以表达活性重组人尿激酶型纤溶酶原激活剂。
Cytotechnology. 2005 Sep;49(1):25-37. doi: 10.1007/s10616-005-4637-7.
2
Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.人尿激酶型纤溶酶原激活物受体在大肠杆菌和中国仓鼠卵巢细胞中的表达:重组蛋白的纯化及鸡多克隆抗体的产生
Electrophoresis. 1995 May;16(5):813-6. doi: 10.1002/elps.11501601134.
3
Pro-urokinase-type plasminogen activator is a substrate for hepsin.尿激酶型纤溶酶原激活剂原是组织蛋白酶原H的一个底物。
J Biol Chem. 2006 Oct 13;281(41):30439-46. doi: 10.1074/jbc.M605440200. Epub 2006 Aug 14.
4
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.前列腺癌DU145细胞表面介导了乳腺丝抑蛋白对尿激酶型纤溶酶原激活剂的抑制作用。
Cancer Res. 2000 Sep 1;60(17):4771-8.
5
Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.尿激酶型纤溶酶原激活剂信号受体复合物的动态组装决定了尿激酶型纤溶酶原激活剂的促有丝分裂活性。
J Biol Chem. 2005 Apr 29;280(17):17449-57. doi: 10.1074/jbc.M413141200. Epub 2005 Feb 21.
6
A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.一种用于研究尿激酶型纤溶酶原激活剂与其受体功能相互作用的竞争性显色测定法。
Biol Chem Hoppe Seyler. 1995 Oct;376(10):587-94. doi: 10.1515/bchm3.1995.376.10.587.
7
A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.尿激酶生长因子结构域与2型纤溶酶原激活物抑制剂的杂合蛋白可抑制尿激酶活性,并与尿激酶受体结合。
Eur J Biochem. 1992 Jul 1;207(1):177-83. doi: 10.1111/j.1432-1033.1992.tb17035.x.
8
Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.受体介导的纤溶酶原激活物功能调节:两种直接膜锚定形式的尿激酶对纤溶酶原的激活作用
J Pept Sci. 2000 Sep;6(9):432-9. doi: 10.1002/1099-1387(200009)6:9<432::AID-PSC279>3.0.CO;2-Q.
9
Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
J Biol Chem. 1998 May 29;273(22):13933-43. doi: 10.1074/jbc.273.22.13933.
10
Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Eur J Biochem. 1989 Dec 22;186(3):523-33. doi: 10.1111/j.1432-1033.1989.tb15238.x.

本文引用的文献

1
Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).通过肝细胞生长因子(HGF)诱导尿激酶型纤溶酶原激活剂(u-PA)增强激素难治性前列腺癌细胞的侵袭能力。
Prostate. 2004 May 1;59(2):167-76. doi: 10.1002/pros.20009.
2
Secretion of macrophage urokinase plasminogen activator is dependent on proteoglycans.巨噬细胞尿激酶型纤溶酶原激活剂的分泌依赖于蛋白聚糖。
Eur J Biochem. 2003 Oct;270(19):3971-80. doi: 10.1046/j.1432-1033.2003.03785.x.
3
Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.尿激酶型纤溶酶原激活剂在前列腺癌患者中的表达的临床意义。
Anticancer Res. 2003 May-Jun;23(3C):2945-50.
4
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.尿激酶型纤溶酶原激活剂蛋白水解活性抑制剂
Curr Pharm Des. 2003;9(19):1483-98. doi: 10.2174/1381612033454649.
5
Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells.β-淀粉样蛋白刺激人脑血管平滑肌细胞中尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR)的表达。
J Biol Chem. 2003 May 23;278(21):19054-61. doi: 10.1074/jbc.M301398200.
6
Aggregation and retention of human urokinase type plasminogen activator in the yeast endoplasmic reticulum.人尿激酶型纤溶酶原激活剂在酵母内质网中的聚集与滞留
BMC Mol Biol. 2002 Oct 7;3:15. doi: 10.1186/1471-2199-3-15.
7
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.尿激酶型纤溶酶原激活剂及其抑制剂PAI-1作为乳腺癌的预后标志物:从初步研究到一级证据研究
Clin Chem. 2002 Aug;48(8):1194-7.
8
The urokinase-type plasminogen activator system in prostate cancer metastasis.尿激酶型纤溶酶原激活物系统在前列腺癌转移中的作用
Cancer Metastasis Rev. 2001;20(3-4):287-96. doi: 10.1023/a:1015539612576.
9
Extracellular proteolysis and angiogenesis.细胞外蛋白水解与血管生成
Thromb Haemost. 2001 Jul;86(1):346-55.
10
Amplification of urokinase gene in prostate cancer.尿激酶基因在前列腺癌中的扩增。
Cancer Res. 2001 Jul 15;61(14):5340-4.

开发哺乳动物悬浮培养体系以表达活性重组人尿激酶型纤溶酶原激活剂。

Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.

机构信息

Department of Biochemistry and Molecular Biology, School of Medicine, University of New Mexico, MSC08 4670, Albuquerque, NM, 87131-0001, USA.

出版信息

Cytotechnology. 2005 Sep;49(1):25-37. doi: 10.1007/s10616-005-4637-7.

DOI:10.1007/s10616-005-4637-7
PMID:19003060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3449752/
Abstract

The development of specific catalytic inhibitors for the serine protease urokinase-type plasminogen activator (uPA) has been hindered due to difficulties in producing sufficient amounts of active recombinant uPA that is catalytically equivalent to native uPA. The purpose of this study was to develop an efficient system for the expression of recombinant human uPA that exhibits comparable proteolytic activity to that of the native protein. Since post-translational modifications (e.g. glycosylations) of uPA are necessary for efficient proteolytic activity, we have used a mammalian cell line [Chinese hamster ovary (CHO)-S] to express recombinant human uPA. CHO-S cells were selected to stably express full-length recombinant human uPA containing a hexahistidine tag at its C-terminus to permit purification by nickel-based affinity chromatography. Secretion of recombinant uPA into the culture media was confirmed by immunoblotting and the presence of an N-linked glycosylation was confirmed by PNGase sensitivity. Enzymatic activity of purified recombinant uPA was demonstrated using zymography and quantitatively compared to native uPA by kinetic analysis using an uPA-specific substrate. Native uPA and the recombinant uPA demonstrated comparable K(m) values (55.7 and 39 muM, respectively). Furthermore, inhibition studies using benzamidine resulted in a K(i) of 195 muM for native uPA, while recombinant uPA had a K(i) of 112 muM. These data indicate that recombinant human uPA expressed by CHO-S cells is functionally comparable to native uPA.

摘要

由于难以产生具有与天然 uPA 催化等效性的足够量的活性重组 uPA,因此针对丝氨酸蛋白酶尿激酶型纤溶酶原激活物(uPA)的特异性催化抑制剂的开发受到了阻碍。本研究的目的是开发一种有效的表达重组人 uPA 的系统,该系统具有与天然蛋白相当的蛋白水解活性。由于 uPA 的翻译后修饰(例如糖基化)对于有效的蛋白水解活性是必需的,因此我们使用了哺乳动物细胞系[中国仓鼠卵巢(CHO)-S]来表达全长重组人 uPA,其 C 末端带有六组氨酸标签,便于通过镍基亲和层析进行纯化。通过免疫印迹证实了重组 uPA 分泌到培养基中,并通过 PNGase 敏感性证实了存在 N 连接的糖基化。通过酶谱法证实了纯化的重组 uPA 的酶活性,并通过使用 uPA 特异性底物进行动力学分析对其与天然 uPA 的活性进行定量比较。天然 uPA 和重组 uPA 的 K(m)值分别为 55.7 和 39 μM,具有可比性。此外,使用苯甲脒进行的抑制研究表明,天然 uPA 的 K(i)值为 195 μM,而重组 uPA 的 K(i)值为 112 μM。这些数据表明,CHO-S 细胞表达的重组人 uPA 在功能上与天然 uPA 相当。